World Library  
Flag as Inappropriate
Email this Article

Tegafur

Article Id: WHEBN0018289561
Reproduction Date:

Title: Tegafur  
Author: World Heritage Encyclopedia
Language: English
Subject: Tegafur/gimeracil/oteracil, Capecitabine, Chemotherapy, Cell-cycle nonspecific antineoplastic agents, Hazardous drugs
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Tegafur

Tegafur
Systematic (IUPAC) name
(RS)-5-Fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione
Clinical data
AHFS/Drugs.com
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Half-life 3.9-11 hours
Identifiers
CAS number  YesY
ATC code L01
PubChem
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  N
Synonyms 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
Chemical data
Formula C8H9FN2O3 
Mol. mass 200.16 g/mol
 N   

Tegafur (INN, BAN, USAN) is a chemotherapeutic fluorouracil prodrug used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-fluorouracil.[1]

Medical uses

As a prodrug to 5-FU it is used in the treatment of the following cancers:[2]

It is often given in combination with drugs that alter its bioavailability and toxicity such as gimeracil, oteracil or uracil.[2] These agents achieve this by inhibiting the enzyme dihydropyrimidine dehydrogenase (uracil/gimeracil) or orotate phosphoribosyltransferase (oteracil).[2]

Adverse effects

The major side effects of tegafur are similar to fluorouracil and include myelosuppression, central neurotoxicity and gastrointestinal toxicity (especially diarrhoea).[2] Gastrointestinal toxicity is the dose-limiting side effect of tegafur.[2] Central neurotoxicity is more common with tegafur than with fluorouracil.[2]

Mechanism of action

It is a prodrug to fluorouracil which is a thymidylate synthase inhibitor.[2]

Pharmacokinetics

It is metabolised into fluorouracil by CYP2A6.[4][5]


Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

}px; border:solid #ccc 1px; background-color:white;">
|}px|alt=Fluorouracil (5-FU) Activity edit|]]
Fluorouracil (5-FU) Activity edit
  1. ^ The interactive pathway map can be edited at WikiPathways: "FluoropyrimidineActivity_WP1601". 

See also

References

  1. ^ El Sayed, YM; Sadée, W (1983). "Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes". Cancer Research 43 (9): 4039–44.  
  2. ^ a b c d e f g Sweetman, S, ed. (14 November 2011). "Martindale: The Complete Drug Reference". Pharmaceutical Press. Retrieved 12 February 2014. 
  3. ^ Ishikawa, T (14 May 2008). "Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma." (PDF). World Journal of Gastroenterology : WJG 14 (18): 2797–2801.  
  4. ^ Nakayama, T; Noguchi, S (January 2010). "Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan." (PDF). The Oncologist 15 (1): 26–36.  
  5. ^ Matt, P; van Zwieten-Boot, B; Calvo Rojas, G; Ter Hofstede, H; Garcia-Carbonero, R; Camarero, J; Abadie, E; Pignatti, F (October 2011). "The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)." (PDF). The Oncologist 16 (10): 1451–1457.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.